ENDRA Life Sciences Inc
NASDAQ:NDRA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.0853
8.84
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ENDRA Life Sciences Inc
ENDRA Life Sciences, Inc. develops medical imaging technology. The company is headquartered in Ann Arbor, Michigan and currently employs 22 full-time employees. The company went IPO on 2017-06-28. The firm has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and stage progression of non-alcoholic fatty liver disease (NAFLD), which untreated, can progress to Non-alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The firm's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
ENDRA Life Sciences, Inc. develops medical imaging technology. The company is headquartered in Ann Arbor, Michigan and currently employs 22 full-time employees. The company went IPO on 2017-06-28. The firm has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and stage progression of non-alcoholic fatty liver disease (NAFLD), which untreated, can progress to Non-alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The firm's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
